lenalidomide

Overview

Cereblon-binding immunomodulatory agent with activity in B-cell lymphomas, including CNS lymphoma salvage regimens.

Evidence in the corpus

• Listed among prior salvage therapies received by r/r CNS lymphoma patients in the MSK ibrutinib phase I/II trial PMID:38995739.

Resistance mechanisms

• Not directly characterized in the corpus.

Cancer types (linked)

• PCNSL
• DLBCLNOS

Sources

• PMID:38995739

This page was processed by crosslinker on 2026-04-09.